share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

極光大麻 | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/08/07 19:16

Moomoo AI 已提取核心訊息

Aurora Cannabis Inc. reported Q1 2025 financial results, achieving positive free cash flow of $6.5 million. Net revenue increased 12% year-over-year to $83.4 million, driven by 13% growth in medical cannabis revenue to $47.2 million. Adjusted EBITDA improved to $4.9 million from $2.6 million last year.The company maintained a strong balance sheet with $182.0 million in cash and cash equivalents. Adjusted gross margin before fair value adjustments on cannabis net revenue was 53%. Aurora continued to focus on its medical cannabis business, which delivered 92% of adjusted gross profit before fair value adjustments.CEO Miguel Martin stated, "Our Q1 results demonstrate continued progress towards sustainable profitability and positive cash flow. Our leading medical cannabis business provides a strong foundation as we pursue growth opportunities in international markets." The company reaffirmed its expectation to achieve positive free cash flow in calendar 2024.
Aurora Cannabis Inc. reported Q1 2025 financial results, achieving positive free cash flow of $6.5 million. Net revenue increased 12% year-over-year to $83.4 million, driven by 13% growth in medical cannabis revenue to $47.2 million. Adjusted EBITDA improved to $4.9 million from $2.6 million last year.The company maintained a strong balance sheet with $182.0 million in cash and cash equivalents. Adjusted gross margin before fair value adjustments on cannabis net revenue was 53%. Aurora continued to focus on its medical cannabis business, which delivered 92% of adjusted gross profit before fair value adjustments.CEO Miguel Martin stated, "Our Q1 results demonstrate continued progress towards sustainable profitability and positive cash flow. Our leading medical cannabis business provides a strong foundation as we pursue growth opportunities in international markets." The company reaffirmed its expectation to achieve positive free cash flow in calendar 2024.
Aurora Cannabis Inc.報告了2025年第一季度財務業績,取得了650萬美元的自由現金流。淨營業收入同比增長12%,達到8340萬美元,主要由於醫療 cannabis 收入增長13%,達到4720萬美元。調整後息稅折舊攤銷前利潤(EBITDA)從去年的260萬美元改善至490萬美元。公司保持了強勁的資產負債表,擁有18200萬美元的現金及現金等價物。調整後的毛利率在 cannabis 淨營業收入的公允價值調整之前爲53%。Aurora持續專注於其醫療 cannabis 業務,該業務在公允價值調整之前貢獻了92%的毛利潤。首席執行官米格爾·馬丁表示:「我們的第一季度業績展示了朝着可持續盈利能力和積極現金流的持續進展。我們領先的醫療 cannabis 業務爲我們在國際市場上追求增長機會奠定了堅實的基礎。」公司重申其期望在2024年度實現積極的自由現金流。
Aurora Cannabis Inc.報告了2025年第一季度財務業績,取得了650萬美元的自由現金流。淨營業收入同比增長12%,達到8340萬美元,主要由於醫療 cannabis 收入增長13%,達到4720萬美元。調整後息稅折舊攤銷前利潤(EBITDA)從去年的260萬美元改善至490萬美元。公司保持了強勁的資產負債表,擁有18200萬美元的現金及現金等價物。調整後的毛利率在 cannabis 淨營業收入的公允價值調整之前爲53%。Aurora持續專注於其醫療 cannabis 業務,該業務在公允價值調整之前貢獻了92%的毛利潤。首席執行官米格爾·馬丁表示:「我們的第一季度業績展示了朝着可持續盈利能力和積極現金流的持續進展。我們領先的醫療 cannabis 業務爲我們在國際市場上追求增長機會奠定了堅實的基礎。」公司重申其期望在2024年度實現積極的自由現金流。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息